← Leaderboards
Matthew Reed
Nob Hill Therapeutics, Inc.
$4,021,634
Attributed
$4,021,634
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,021,634 · 3
By mechanism
R44$3,722,576 · 2
R43$299,058 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Small Business Innovation Research Grant”
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
- Molly Wasko · University Of Alabama At Birmingham$18,764,568
- Ashkan Vaziri · Biosensics, Llc$17,149,241
- Bryan L McLaughlin · Micro-Leads, Inc.$11,109,320
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,485,488
- Matthew Golden · Maphabit, Inc.$8,701,960
Research focus
Small Business Innovation Research GrantBreathingPharmaceutical PreparationsScale UpProgramsDoseLungLegal PatentParticle SizeSafetyPowder Dose FormDevicesDrug KineticsToxicologyInhalationFormulationCharacteristicsInhalatorsAerosolsClinical ResearchNebulizerPulmonary FunctionRattusReporting
Grant awards (5)
Aerosolized Epigenetic Therapy for Metastatic Lung Cancer$1,138,913
R44 · FY2025 · CA · contact PI
Aerosolized Epigenetic Therapy for Metastatic Lung Cancer$861,087
R44 · FY2023 · CA · contact PI
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections$564,303
R44 · FY2023 · HL · contact PI
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections$1,158,273
R44 · FY2022 · HL · contact PI
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections$299,058
R43 · FY2020 · HL · contact PI